Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer by  et al.
FERTILITY PRESERVATION
Recommendations for fertility preservation in patients
with lymphoma, leukemia, and breast cancer
ISFP Practice Committee & S. Samuel Kim &
Jacques Donnez & Pedro Barri & Antonio Pellicer &
Pasquale Patrizio & Zev Rosenwaks & Peter Nagy &
Tommaso Falcone & Claus Andersen & Outi Hovatta &
Hamish Wallace & Dror Meirow & Debra Gook &
Seok H Kim & Chii-Ruey Tzeng & Shuetu Suzuki &
Bunpei Ishizuka & Marie-Madeleine Dolmans
Received: 19 April 2012 /Accepted: 25 April 2012 /Published online: 31 May 2012
# The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract Fertility issues should be addressed to all
patients in reproductive age before cancer treatment. In
men, cryopreservation of sperm should be offered to all
cancer patients in reproductive age regardless of the risk
of gonadal failure. In women, the recommendation of
fertility preservation should be individualized based on
multiple factors such as the urgency of treatment, the
age of the patient, the marital status, the regimen and
dosage of cancer treatment.
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Fertility issues should be addressed to all patients in repro-
ductive age before cancer treatment. In cases where the
Capsule The ISFP Practice committee developed recommendations
for fertility preservation in patients with lymphoma, leukemia, and
breast cancer.
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DOI 10.1007/s10815-012-9786-ypatient is a minor, it is recommended to obtain assent from a
patient in addition to signed consent from the parents. In
men, cryopreservation of sperm should be offered to all
cancer patients in reproductive age regardless of the risk of
gonadal failure. In women, the recommendation of fertility
preservation should be individualized based on multiple
factors such as the urgency of treatment, the age of the
patient, the marital status, the regimen and dosage of cancer
treatment. If the risk of gonadal failure is very low (such as
ABVD), fertility preservation may not be required. On the
other hand, the patient who undergoes hematopoietic stem
cell transplant (HSCT) should strongly consider fertility
preservation. In principle, embryo cryopreservation or oo-
cyte cryopresevtion is recommended as a fertility preserva-
tion option, if there is enough time for ovarian stimulation
before initiation of cancer therapy. If cancer treatment can-
not be delayed or ovarian stimulation is contraindicated,
ovarian tissue cryopreservation should be the first option
of fertility preservation.
Incidence and survival (cited from http://seer.cancer.gov)
1) Lymphoma
Hodgkin lymphoma (HL): It is estimated that 4,010
women are newly diagnosed with HL in 2011. Among
those, approximately 1,760 are under age 34. Approximate-
ly, 12.3 % were under age 20, 32 % between 20–34, and
15.8 % between 35–44. (2004–2008). The overall 5-year
relative survival for 2001–2007 was 84 %. Currently, 5-year
relative survival for women under age 49 is 90-95 %.
Non Hodgkin lymphoma (NHL): It is estimated that
30,300 women are diagnosed with NHL in 2011. Among
those, approximately 1,670 are under age 34. Approximate-
ly 1.7 % were diagnosed under age 20, 3.8 % between 20–
34, and 6.8 % between 35 and 44. The overall 5-year
relative survival for 2001–2007 was 67 %. Currently, 5-
year relative survival for women under age 49 is 80-85 %.
2) Leukemia
Acute lymphocytic leukemia (ALL): It is estimated
that 2,410 women are newly diagnosed with ALL in
2011. Among those, approximately 1,750 are under age
34. Approximately, 60.3 % were under age 20, 10.3 %
between 20–34, and 5.9 % between 35–44. (2004–
2008). The overall 5-year relative survival for 2001–
2007 was 64 %.
Chronic lymphocytic leukemia (CLL): The incidence is
about 6,000/year, but it is very rare disease in women with
age under 34 (0.3 %). The overall 5-year relative survival
for 2001–2007 was 78 %.
Acute myeloid leukemia (AML): It is estimated that
6,120 women are diagnosed with AML in 2011. Among
those, approximately 810 are under age 34. Approximately,
6.1 % were under age 20, 6.6 % between 20–34, and 6.6 %
between 35–44. (2004–2008). The overall 5-year relative
survival for 2001–2007 was 23 %.
Chronic myeloid leukemia (CML): It is estimated that
2,150 women are newly diagnosed with HL in 2011.
Among those, approximately 220 are under age 34. Approx-
imately, 2.6 % were under age 20, 7.7 % between 20–34,
and 9.9 % between 35–44. (2004–2008). The overall 5-year
relative survival for 2001–2007 was 57 %.
3) Breast Cancer
It is estimated that 230,480 women are newly diagnosed
with breast cancer in 2011. Among those, approximately
11,000 are under age 40. From 2004–2008, 0 % were
diagnosed under age 20, 1.9 % between 20–34, and
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is approximately 90 %. In US there are approximately 2.6
million women alive with a history of breast cancer.
Treatment and its effects on gonadal function
1) Lymphoma
Chemotherapy induced gonadal dysfunction depends on
the age at first treatment and the treatment protocols. The
risk of gonadal dysfunction after cancer treatment is low in
pediatric population. NHL patients treated with chemother-
apy (except HSCT) have very low risk of developing pri-
mary ovarian insufficiency (POI). Here are the common
treatment regimens for HL and NHL.
HL
ABVD (adriamycin, bleomycin, vinblastine, dacarbazine): POI
rates are less than 10 % in the reproductive age; BEACOPP
(bleomycin, etoposide, adriamycin, cyclophosphamide, onco-
vin, procarbazine, predisone): POI rates are around 50 % in
those under 30 years; MOPP (chlormethamine, oncovine: pro-
carbazine, prednisone): POI rates are 20- 50 % in women in
reproductive age; HSCT: POI rates are 70-100 %, post-
treatment parenthood rates are as low as 3-8 % [1].
NHL
CHOP (cyclophosphamide, doxorubicin, vincristine, predis-
one): POI rates are around 5 %, pregnancy rates after treat-
ment are 50 % [2]; Hyper-CVAD (cyclophosphamide,
vincristine, doxorubicin, dexamethasone, cytarabine, metho-
trexate): POI rates are 14 %, pregnancy rates after treatment
are 43 % [3]; HSCT: POI rates are 70-100 % [1].
2) Leukemia
The risk of infertility in patients with ALL or AML
(unless treated with HSCT) is very low as contemporary
treatment protocols entails lower doses of alkylating
agents or are devoid of alkylating agents. CML can be
treated with tyrosin kinase inhibitors such as imatinib or
rituximab. Tyrosin kinase inhibitors may not impair
fertility in humans, but there is insufficient data on
these medications on reproductive potential. Of note,
tyrosin kinases are important for follicle growth and
development.
3) Breast cancer
Adjuvant chemotherapy after surgery or neo-adjuvant che-
motherapy before surgery has an important role in breast
cancer treatment, as it is likely to reduce the risk of recurrence
and death from breast cancer by a relative factor of 50 % or
more[4].Theprimaryfactorsaffectingchemotherapyinduced
gonadotoxicity are age of the patient, and dose and number of
cycles of the alkylating agent received. For example, the risk
of amenorrhea after six cycle of CMF (cyclophosphamide,
methotrexate, fluorouracil) or four cycyles of AC (anthracy-
cline,cyclophosphamide) is33%,onthe other hand, 50-65 %
ofpatientswillexperienceamenorrheaaftertreatmentwithsix
cycles of FEC (fluorouracil, epirubicin, cyclophosphamide),
or FAC (fluorouracil, doxorubicin, cyclophosphamide), or
four cycles of AC followed by four of docetaxel [4].
Recommendations for fertility preservation
All patients who desire to preserve fertility should be counseled
and informed about currently available fertility preservation
options by fertility specialists. Recommendations should be
individualized and should not violate the ethical principles. In
general, fertility preservation before cancer treatment is strong-
ly recommended if the chance of losing fertility is over 30 %
with cancer therapy. In pediatric patients, the risk of gonadal
failure with chemotherapy is very low in the absence of HSCT.
1) Lymphoma
Post-pubertal male: Cryopreservation of spermatozoa.
GnRHa co-treatment is not recommended in male.
Pre-pubertal male: No good option. Cryopreservation of
testicular tissue may be available in some centers as a
strictly experimental procedure.
Post-pubertal female: Cryopreservation of embryos or
cryopreservation of oocytes is recommended if cancer treat-
ment can be delayed. However, immediate treatment is
required in most of lymphoma patients and thus cryopreser-
vation of ovarian tissue should be considered as a fertility
preservation option. Alternatively, immature oocyte retriev-
al followed by IVM and cryopreservation of oocytes or
embryos can be considered. The protective effect of GnRHa
is questionable and controversial. However, GnRHa co-
treatment can be considered for female patients undergoing
chemotherapy (not for HSCT) if there is no other option.
Pre-pubertal female: Ovarian tissue cryopreservation, if
the risk of ovarian failure after cancer treatment is high
enough to justify the procedure.
2) Leukemia
Post-pubertal male: cryopreservation of spermatozoa.
Pre-pubertal male: no currently available option.
Post-pubertal female: No ideal option to date. However,
cryopreservation of ovarian tissue should be considered
before HSCT. Any harvested tissue from leukemia patients
should not be used for auto-transplantation because of high
risk of cancer cell reintroduction. Alternatively, immature
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oocytes or embryos can be considered.
Pre-pubertal female: Ovarian tissue cryopreservation be-
fore HSCT. Any harvested tissue from leukemia patients
should not be used for auto-transplantation because of high
risk of cancer cell reintroduction. In the absence of HSCT,
fertility preservation before chemotherapy is not necessary.
3) Breast cancer
It is recommended that fertility preservation consultation is
arranged at the time of initial diagnosis. In many cases, young
breast cancer patients require adjuvant chemotherapy after
surgery (mastectomy or lumpectomy). The best time for fertil-
ity preservation is after surgery and before adjuvant therapy.
Cryopreservation of embryos or cryopreservation of oocytes is
recommended as a fertility preservation option before chemo-
therapy. As cryopreservation of embryos or oocytes requires
controlled ovarian stimulation (COS), the risk of increased
peak estradiol levels with COS in breast cancer patients (espe-
cially with ER+tumor) should be discussed before the proce-
dure. The COS strategy using tamoxifen or letrozole in
conjunction with gonadotropin may be safer for women with
ER+tumor. For women who require urgent cancer treatment
such as neo-adjuvant chemotherapy, cryopreservation of ovar-
ian tissue should beconsidered. Alternatively, immature oocyte
retrieval followed by IVM and cryopreservation of oocytes or
embryos can be considered.
(Addendum)
Criteria for ovarian tissue banking (by S. Samuel Kim)
1) Age: under 37 years (may be individualized based on
the status of ovarian reserve)
2) Ovarian function: premenopausal by FSH, antral folli-
cle count (AFC) or AMH
3) Communication with oncologists: cancer treatment
plan, prognosis
4) When embryo freezing or oocyte freezing is not indicat-
ed:delayingcancertreatment isnotacceptable, hormon-
al stimulation is not permitted, ART is not allowed.
5) Prepubertal girls who do not have any other options
6) High risk for POF (when significant loss of ovarian
follicles is anticipated with cancer therapy)
7) Informed consent from adult patients
8) Informed consent from parents/guardians as well as
informed assent from minors, if the patient is less than
18 years
9) Physically and mentally healthy enough for surgery
10) Desires to have a child in the future (preferably before
the age 50)
11) Thorough patient counseling: currently available fer-
tility preservation options including embryo and oo-
cyte cryopreservation, how to use cryobanked ovarian
tissue for fertility restoration
12) Should understand experimental nature and potential
risks of cancer cell transmission.
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